2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|April 15, 2014
- Pharmaceutical Technology-04-15-2014
- Volume 2014 eBook
- Issue 1
Safety by Design—Mitigating the Risk of Medication Errors Through Product Design
Author(s)Adeline Siew, PhD
Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.
Advertisement
The increasing prevalence and high cost of medication errors have prompted regulators and manufacturers to look into the role of product design in ensuring the safe and correct use of medicines. Experts share insights on how product appearance such as size, shape, color, and imprint can make a difference in reducing medication errors.
Download
.
Articles in this issue
over 12 years ago
Continuous Manufacturing for Solid-Dosage Drug Productionover 12 years ago
Using Modular Systems in Solid-Dosage Manufacturingover 12 years ago
Advances in Hot-Melt Extrusion Manufacturingover 12 years ago
Selection of Excipients in Generic FormulationsAdvertisement
Related to this article
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
Inluriyo-Verzenio Combo Doubles PFS, Adds Oral Complexity
3
Can AI Agents Satisfy CGMP Documentation Requirements?
4
PharmTech AI Pulse Check: Fixing AI Slop at the Source
5